Shire (LON:SHP)‘s stock had its “buy” rating restated by research analysts at Citigroup in a research note issued to investors on Friday. They presently have a GBX 5,500 ($74.02) price objective on the biopharmaceutical company’s stock. Citigroup’s price target suggests a potential upside of 51.72% from the company’s current price.

A number of other research analysts also recently issued reports on SHP. Shore Capital reissued a “buy” rating on shares of Shire in a research note on Wednesday, September 20th. Barclays reissued an “equal weight” rating and issued a GBX 4,000 ($53.84) price objective on shares of Shire in a research note on Monday, October 30th. Kepler Capital Markets reissued a “buy” rating and issued a GBX 4,600 ($61.91) price objective on shares of Shire in a research note on Wednesday, November 1st. Berenberg Bank dropped their price objective on Shire from GBX 6,000 ($80.75) to GBX 5,900 ($79.41) and set a “buy” rating on the stock in a research note on Tuesday, October 24th. Finally, Liberum Capital reissued a “buy” rating and issued a GBX 4,200 ($56.53) price objective on shares of Shire in a research note on Monday, November 20th. Four investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of GBX 5,277.78 ($71.03).

Shire (LON:SHP) traded up GBX 89.03 ($1.20) during midday trading on Friday, hitting GBX 3,625 ($48.79). The company’s stock had a trading volume of 1,178,446 shares, compared to its average volume of 2,670,000. Shire has a 1 year low of GBX 3,435.50 ($46.24) and a 1 year high of GBX 5,067 ($68.20).

In related news, insider Anne Minto acquired 190 shares of the stock in a transaction dated Friday, September 29th. The stock was purchased at an average cost of GBX 3,785 ($50.94) per share, with a total value of £7,191.50 ($9,679.00).

ILLEGAL ACTIVITY WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/08/shire-shp-given-buy-rating-at-citigroup.html.

Shire Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire (LON:SHP)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.